INS and metabolic syndrome: Moreover, glucocorticoids trigger hepatic gluconeogenesis, and inhibit or generate an insulin effect on skeletal muscle and adipose tissue, respectively, thus promoting visceral adiposity and the metabolic syndrome [42].